PL2061427T3 - Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania - Google Patents

Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania

Info

Publication number
PL2061427T3
PL2061427T3 PL07808579T PL07808579T PL2061427T3 PL 2061427 T3 PL2061427 T3 PL 2061427T3 PL 07808579 T PL07808579 T PL 07808579T PL 07808579 T PL07808579 T PL 07808579T PL 2061427 T3 PL2061427 T3 PL 2061427T3
Authority
PL
Poland
Prior art keywords
active substance
pharmaceutically active
granulate
emulsifier
manufacture
Prior art date
Application number
PL07808579T
Other languages
English (en)
Inventor
Hubert Clemens Pellikaan
Pieter Sebastiaan Vermeulen
Johannes Caspar Mathias Elizabeth Bender
Cid Maria Vanesa Fernandez
Original Assignee
Echo Pharmaceuticals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2061427(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Echo Pharmaceuticals Bv filed Critical Echo Pharmaceuticals Bv
Publication of PL2061427T3 publication Critical patent/PL2061427T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07808579T 2006-09-15 2007-09-14 Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania PL2061427T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06120741 2006-09-15
PCT/NL2007/050448 WO2008033023A2 (en) 2006-09-15 2007-09-14 Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture
EP07808579A EP2061427B1 (en) 2006-09-15 2007-09-14 Granulate containing a pharmaceutically active substance and an emulsifier and method for its manufacture

Publications (1)

Publication Number Publication Date
PL2061427T3 true PL2061427T3 (pl) 2011-12-30

Family

ID=37809291

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07808579T PL2061427T3 (pl) 2006-09-15 2007-09-14 Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania

Country Status (10)

Country Link
US (1) US20100034888A1 (pl)
EP (1) EP2061427B1 (pl)
JP (2) JP2010503663A (pl)
CN (1) CN101594848B (pl)
AT (1) ATE516796T1 (pl)
AU (1) AU2007295178B2 (pl)
CA (1) CA2664311C (pl)
ES (1) ES2370062T3 (pl)
PL (1) PL2061427T3 (pl)
WO (1) WO2008033023A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2061427T3 (pl) * 2006-09-15 2011-12-30 Echo Pharmaceuticals Bv Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania
WO2008033024A2 (en) * 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
ES2623328T3 (es) * 2009-09-18 2017-07-11 Sitec Pharmabio Sl Procedimiento para la deshidratación de productos en polvo
US8383851B2 (en) 2010-09-15 2013-02-26 Caravan Ingredients Inc. Lactylate synthesis methods using dilactides
ES2600465T3 (es) * 2012-05-07 2017-02-09 Echo Pharmaceuticals B.V. Granulado que contiene cannabinoide, método para su producción y unidad de dosificación oral que comprende tal granulado
CA2929321C (en) 2013-10-29 2022-04-05 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US9616025B2 (en) * 2013-10-29 2017-04-11 Echo Pharmaceuticals B.V. Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
CN104688734B (zh) * 2013-12-04 2017-08-15 长春海悦药业股份有限公司 一种含有苯磺酸左旋氨氯地平的药物组合物
US20180007924A9 (en) 2015-05-18 2018-01-11 5071, Inc. Homogenous cannabis compositions and methods of making the same
MX382609B (es) * 2016-07-25 2025-03-13 Canopy Growth Corp Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
US20190015383A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
EP3946262B1 (en) * 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
GB8730011D0 (en) * 1987-12-23 1988-02-03 Smithkline Dauelsberg Pharmaceutical compositions
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
DK0621777T3 (da) * 1992-01-17 1996-10-21 Alfatec Pharma Gmbh Pellets indeholdende aktivt stof og med en matrix af hydrofile makromolekyler, og fremgangsmåde til deres fremstilling
ATE216577T1 (de) * 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
AU676315B2 (en) * 1993-06-30 1997-03-06 Takeda Chemical Industries Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
DE60014255T2 (de) * 1999-07-06 2005-11-03 Dsm Ip Assets B.V. Zusammensetzung, die fettlösliche Substanzen in einer Kohlenhydratmatrix enthält
FR2797398B1 (fr) * 1999-08-11 2002-10-18 Mainelab Microparticules pour administration pulmonaire
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
WO2002070013A1 (en) * 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Utilization of spray-dried powder containing sugar alcohol
UA79281C2 (en) * 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
MXPA04011808A (es) * 2002-05-31 2005-09-12 Univ Mississippi Liberacion transmucosica de canabinoides.
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
GB0300339D0 (en) * 2003-01-08 2003-02-05 Bradford Particle Design Ltd Particle formation
US7423004B2 (en) * 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
WO2004071645A2 (en) * 2003-02-07 2004-08-26 Ferro Corporation Method and apparatus for supercritical fluid assisted particle production
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
EP1641437A4 (en) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
US20050163843A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
BRPI0513395A (pt) * 2004-07-16 2008-05-06 Novartis Ag uso de um esteróide para aumentar a permeabilidade cutánea
EP1757361A1 (en) * 2005-08-23 2007-02-28 Feyecon Development & Implementation B.V. Process for the preparation of encapsulates through precipitation
ATE481165T1 (de) * 2005-12-22 2010-10-15 Inst Nat Sante Rech Med Verfahren zur herstellung von teilchen aus einer emulsion in überkritischem oder flüssigem co2
PL2061427T3 (pl) * 2006-09-15 2011-12-30 Echo Pharmaceuticals Bv Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania

Also Published As

Publication number Publication date
CN101594848B (zh) 2014-10-29
CA2664311A1 (en) 2008-03-20
ES2370062T3 (es) 2011-12-12
WO2008033023A2 (en) 2008-03-20
AU2007295178A1 (en) 2008-03-20
WO2008033023A3 (en) 2008-09-12
EP2061427B1 (en) 2011-07-20
CA2664311C (en) 2015-08-18
AU2007295178B2 (en) 2013-04-18
CN101594848A (zh) 2009-12-02
ATE516796T1 (de) 2011-08-15
JP2014114302A (ja) 2014-06-26
JP2010503663A (ja) 2010-02-04
US20100034888A1 (en) 2010-02-11
EP2061427A2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
PL2061427T3 (pl) Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania
WO2007053696A3 (en) Rnai inhibition of influenza virus replication
WO2006009836A3 (en) Tdf-related compounds and analogs thereof
UA104601C2 (uk) Модулятори регулятора трансмембранної провідності при муковісцидозі
EA200702562A1 (ru) Способ получения хлоргидрина путем конверсии полигидроксилированных алифатических углеводородов
AU2002326072A1 (en) Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
MY147661A (en) Fused bicycloheterocycle substituted azabicyclic alkane derivatives
WO2008033562A3 (en) Kinase inhibitor compounds
WO2008009415A3 (de) 4-heteroaryl-substituierte 1-aminocyclohexan-1- und cyclohexen-1-derivate mit wirkung auf das opiod rezeptor system
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2009065738A3 (de) Polyoxyalkylenamine zur verbesserten duftausbeute
WO2010049454A3 (en) Antimicrobial composition from copepods
ZA201003221B (en) Tea composition and process for the manufacture thereof
EP1546098A4 (en) 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 | HEXANDERIVATES SUITED AS MUSCARIN RECEPTOR ANTAGONISTS
WO2009149955A3 (de) Verfahren zur auswahl eines geeigneten hilfsstoffs für die herstellung von festen dispersionen für pharmazeutische formulierungen
EA200900646A1 (ru) Способ получения твердой фармацевтической композиции, содержащей валсартан
UA97965C2 (ru) Замещенные пиразолы, содержащая их композиция, способ их получения и применения
WO2007035872A3 (en) Tdf-related compounds and analogs thereof
WO2008037359A3 (de) Wirkstoff enthaltende stabilisierte feste arzneimittelformen und verfahren zu ihrer herstellung
WO2008104880A3 (en) Stable solid dosage forms of an antidepressant
UA97942C2 (ru) Твердая фармацевтическая композиция, содержащая валсартан
WO2006035282A3 (en) Muscarinic receptor antagonists
WO2006135413A3 (en) Encapsidation system for production of recombinant virus-like particles
MX2007011016A (es) Microemulsiones de compuestos aglutinantes de receptores canabinoides.
WO2006105482A3 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same